PMID- 26445809
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181113
IS  - 1661-4917 (Electronic)
IS  - 0004-069X (Print)
IS  - 0004-069X (Linking)
VI  - 64
IP  - 2
DP  - 2016 Apr
TI  - HMGB1 Inhibition During Zymosan-Induced Inflammation: The Potential Therapeutic 
      Action of Riboflavin.
PG  - 171-6
LID - 10.1007/s00005-015-0366-6 [doi]
AB  - Sepsis, also known as systemic inflammatory response syndrome, is a 
      life-threatening condition caused by a pathogenic agent and leading to multiple 
      organ dysfunction syndrome. One of the factors responsible for the excessive 
      intensification of the inflammatory response in the course of inflammation is 
      high-mobility group protein B1 (HMGB1). HMG-1 is a nuclear protein which, after 
      being released to the intercellular space, has a highly pro-inflammatory effect 
      and acts as a late mediator of lethal damage. The purpose of this study was to 
      examine whether the anti-inflammatory action of riboflavin is accompanied by 
      inhibition of HMGB1 release during peritoneal inflammation and zymosan 
      stimulation of macrophages. Peritonitis was induced in male BALB/c and C57BL/6J 
      mice via intraperitoneal injection of zymosan (40 mg/kg). RAW 264.7 macrophages 
      were activated with zymosan (250 microg/ml). Riboflavin (mice, 50 mg/kg; RAW 264.7, 
      25 microg/ml) was administered 30 min before zymosan, simultaneously with, or 2, 4, 
      6 h after zymosan. Additionally, mRNA expression of HMGB1 and its intracellular 
      and serum levels were evaluated. The research showed that riboflavin 
      significantly reduces both the expression and the release of HMGB1; however, the 
      effect of riboflavin was time-dependent. The greatest efficacy was found when 
      riboflavin was given 30 min prior to zymosan, and also 2 and 4 h (C57BL/6J; RAW 
      264.7) or 4 and 6 h (BALB/c) after zymosan. Research showed that riboflavin 
      influences the level of HMGB1 released in the course of inflammation; however, 
      further study is necessary to determine its mechanisms of action.
FAU - Mazur-Bialy, Agnieszka Irena
AU  - Mazur-Bialy AI
AD  - Department of Ergonomics and Exercise Physiology, Faculty of Health Science, 
      Jagiellonian University Medical College, Grzegorzecka 20, 31-531, Krakow, Poland. 
      agnieszka.mazur@uj.edu.pl.
FAU - Pochec, Ewa
AU  - Pochec E
AD  - Department of Glycoconjugate Biochemistry, Institute of Zoology, Jagiellonian 
      University, Krakow, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151007
PL  - Poland
TA  - Arch Immunol Ther Exp (Warsz)
JT  - Archivum immunologiae et therapiae experimentalis
JID - 0114365
RN  - 0 (HMGB1 Protein)
RN  - 9010-72-4 (Zymosan)
RN  - TLM2976OFR (Riboflavin)
SB  - IM
MH  - Animals
MH  - HMGB1 Protein/genetics/immunology/*metabolism
MH  - Humans
MH  - Macrophages/*drug effects/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Peritonitis/chemically induced/*drug therapy
MH  - Riboflavin/*therapeutic use
MH  - Sepsis/*drug therapy
MH  - Zymosan/administration & dosage
PMC - PMC4805693
OTO - NOTNLM
OT  - HMGB1
OT  - Inflammation
OT  - Macrophages
OT  - Peritonitis
OT  - Sepsis
OT  - Vitamin B2
EDAT- 2015/10/09 06:00
MHDA- 2016/12/15 06:00
PMCR- 2015/10/07
CRDT- 2015/10/09 06:00
PHST- 2015/02/12 00:00 [received]
PHST- 2015/08/31 00:00 [accepted]
PHST- 2015/10/09 06:00 [entrez]
PHST- 2015/10/09 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2015/10/07 00:00 [pmc-release]
AID - 10.1007/s00005-015-0366-6 [pii]
AID - 366 [pii]
AID - 10.1007/s00005-015-0366-6 [doi]
PST - ppublish
SO  - Arch Immunol Ther Exp (Warsz). 2016 Apr;64(2):171-6. doi: 
      10.1007/s00005-015-0366-6. Epub 2015 Oct 7.